The epidermal growth factor receptor (EGFR) is upregulated in squamous cell carcinomas of the head and neck (SCCHN) where EGFR expression levels in the tumor correlate with decreased survival. The EGFR monoclonal antibody, cetuximab, was FDA-approved in 2006 for the treatment of SCCHN and is the first new drug for this cancer in 45 years. However, despite the ubiquitous expression of EGFR in SCCHN tumors, the clinical response rate to cetuximab as single agent therapy is limited, underscoring the importance of elucidating the mechanisms of persistent tumor growth in the setting of wild-type EGFR blockade. We have accumulated extensive evidence that GPCR-mediated signaling through EGFR-dependent and EGFR-independent pathways contributes to SCCHN growth and survival. Patients who do not respond to cetuximab are likely to succumb to their head and neck cancer. We currently do not know how to identify SCCHN patients who will benefit from EGFR targeting. Our working hypothesis is that persistent GPCR signaling in the setting of EGFR blockade contributes to tumor progression. Completion of these studies will elucidate mechanisms of resistance to EGFR targeting strategies thus facilitating the design of therapeutic regimens to enhance clinical response. To accomplish the goals of this proposal, we will: 1) determine the GPCR-stimulated pathways in SCCHN that are activated upstream or downstream of EGFR with the goal of identifying therapeutic targets;2) elucidate the EGFR-independent pathways induced by GPCR in SCCHN;and 3) determine the antitumor effects of EGFR targeting in combination with key GPCR signaling intermediates in preclinical SCCHN models.

Public Health Relevance

The proposed studies will elucidate the mechanisms of resistance to EGFR targeting strategies in preclinical models of squamous cell carcinoma of the head and neck. Specifically, we will test the hypothesis that persistent G-protein-coupled receptor (GPCR) signaling in the setting of EGFR blockade contributes to limited clinical responses to EGFR targeting in SCCHN. In addition, we will test the hypothesis that GPCR signaling contributes to cetuximab resistance in 2 SCCHN patient cohorts and that GPCR targeting in combination with EGFR blockade modulates expression of proteins and phosphoproteins in human SCCHN tumors from subjects treated on a clinical protocol.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA098372-07
Application #
7803000
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Salnikow, Konstantin
Project Start
2002-12-01
Project End
2014-01-31
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
7
Fiscal Year
2010
Total Cost
$240,092
Indirect Cost
Name
University of Pittsburgh
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Stabile, L P; Egloff, A M; Gibson, M K et al. (2017) IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. Oral Oncol 69:38-45
Brand, Toni M; Hartmann, Stefan; Bhola, Neil E et al. (2017) Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res 23:3072-3083
Bhola, Neil E; Jansen, Valerie M; Koch, James P et al. (2016) Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res 76:440-52
Hartmann, Stefan; Bhola, Neil E; Grandis, Jennifer R (2016) HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clin Cancer Res 22:4005-13
Li, Hua; Wheeler, Sarah; Park, Yongseok et al. (2016) Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Mol Cancer Res 14:278-86
Geiger, Jessica L; Bauman, Julie E; Gibson, Michael K et al. (2016) Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head Neck 38:1759-1764
Van Allen, Eliezer M; Lui, Vivian W Y; Egloff, Ann Marie et al. (2015) Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol 1:238-44
Hammerman, Peter S; Hayes, D Neil; Grandis, Jennifer R (2015) Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov 5:239-44
Gross, Neil D; Bauman, Julie E; Gooding, William E et al. (2014) Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 20:3289-98
Li, Hua; Wawrose, John S; Gooding, William E et al. (2014) Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Mol Cancer Res 12:571-82

Showing the most recent 10 out of 50 publications